Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in C:\inetpub\wwwroot\technology_detail.php on line 331
 Technology Detail


The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

Agents to inhibit pathological angiogenesis


Stanford Reference:

01-246


Abstract


Researchers in Prof. John Cooke’s laboratory have developed patented methods for suppressing angiogenesis with nicotine receptor antagonist compounds. This concept was initially validated by a variety of preclinical in vitro and in vivo model systems. Further development of the antagonist compounds could lead to therapies for cancer (inhibiting neovascularization and tumor growth), macular degeneration and other conditions characterized by excessive angiogenesis.

Stage of Research
Pre-clinical studies have provided proof-of-concept that an antagonist of the nicotinic acetylcholine receptor can inhibit choroidal neovascularization. A topical formulation of mecamylamine (an antagonist of the nicotinic receptor) has been shown to provide for effective levels of the nicotinic antagonist in the choroid and retina in three different animal models including primate. A Phase I study has shown tolerability of the topical formulation. The topical formulation has been studied in a small phase II study in diabetic macular edema. A larger phase II study of the topical formulation in age-related macular degeneration is nearing completion.

Related nicotine receptor technology
The inventors have also validated the nicotine receptor’s role in promoting angiogenesis (to treat ischemic conditions) and in stem cell recruitment. These patented technologies are described in “Therapeutic angiogenesis by targeting the nicotine receptor” (Stanford Docket S99-081) and “Nicotine for Stem Cell and Progenitor Cell Recruitment” (Stanford Docket S00-149).


Applications


  • Therapeutic - treatment of disorders characterized by pathological angiogenesis, such as:
    • cancer
    • ocular diseases - diabetic retinopathy, macular degeneration, retrolental fibroplasia
    • pulmonary diseases - idiopathic pulmonary fibrosis, acute adult respiratory distress
    • atherosclerotic plaques
    • psoriasis

Advantages


  • Novel target and pathway
  • Known class of drugs - some agents have already been used safely in humans and are well characterized with respect to their pharmacokinetics, safety and adverse effects

Publications



Related Web Links



Innovators & Portfolio



Patent Status



Date Released

 1/14/2011
 

Licensing Contact


Chu Chang, Licensing Associate
650-723-0652 (Direct)
Login to Request Information

[-] Map/Timeline

92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
99-081 Nicotine and Nicotine Agonists for Therapeutic Angiogenesis
00-104 DNA nanocircles for telomere elongation in vivo and ex vivo

more technologies »

Related Keywords


therapeutic: anticancer   age related macular degeneration   anti-angiogenesis   atherosclerosis   diseases: atherosclerosis   antiangiogenesis   idiopathic pulmonary fibrosis   macular degeneration   neovascularization   retinopathy   nAChR   nicotine   
 

   

  

Also of Interest...
92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
99-081 Nicotine and Nicotine Agonists for Therapeutic Angiogenesis
00-104 DNA nanocircles for telomere elongation in vivo and ex vivo

Recently Viewed...
S01-246 Agents to inhibit pathological angiogenesis